Land: Israel
Språk: engelska
Källa: Ministry of Health
ZOLPIDEM TARTRATE
SANOFI ISRAEL LTD
N05CF02
TABLETS EXTENDED RELEASE
ZOLPIDEM TARTRATE 6.25 MG
PER OS
Required
SANOFI WINTHROP INDUSTRIE, FRANCE
ZOLPIDEM
ZOLPIDEM
For the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset).
2014-11-30
1986 - )تارضحتسم( ةلديصلا ةمظنأ بجومب كلهتسملل ةرشن طقف بيبط ةفصو بجومب ءاودلا ق ّ وسي غلم 6.25 رآ .يس نايبمأ غلم 12.5 رآ .يس نايبمأ دتمم ريرحت تاذ صارقأ :اهتيمكو ةلاعفلا ةداملا غلم 6.25 تارترات ميديپلوز :ىلع غلم 6.25 رآ .يس نايبمأ نم صرق لك يوتحي Zolpidem Tartrate 6.25 mg غلم 12.5 تارترات ميديپلوز :ىلع غلم 12.5 رآ .يس نايبمأ نم صرق لك يوتحي Zolpidem Tartrate 12.5 mg ةماه تامولعم" 2 ةرقفلا رظنأ ـ رضحتسملا يف ةيساسحلا تادلومو ةلاعفلا ريغ داوملا ."ةيفاضإ تامولعم" 6 ةرقفلاو "ءاودلا تابكرم ضعب نع ةزجوم تامولعم ىلع ةرشنلا هذه يوتحت .ءاودلل كلامعتسإ لبق اهتياهن ىتح نعمتب ةرشنلا أرقإ .يلديصلا وأ بيبطلا عجار ،ةيفاضإ ةلئسأ كيدل ترفوت اذإ .ءاودلا نع مهتلاح نأ كل ادب ولو ىتح مهرضي دق وهف .نيرخلآل هيطعت لا .كلجأ نم جلاعلل ءاودلا اذه فص ُ و .كتلاحل ةهباشم ةيبطلا ؟ءاودلا صصخم ضرغ يلأ )1 ىلع ظافحلا يف ةبوعص وأ/و مونلا ىلإ دولخلا يف تابوعصب لثمتملا قرلأا جلاعل صصخم ءاودلا .مونلا ةيرارمتسإ .ةئدهملاو ةمونملا داوملا نم :ةيجلاعلا ةليصفلا ءاودلا لامعتسإ لبق )2 :اذإ ءاودلا لامعتسإ زوجي لا ةقايس لثم) مونلا للاخ يعولا نع جراخ كولس نم رآ .يس نايبمأ لوانت دعب ةرم تاذ تيساق ● يذلا تقولا يف ةيسنج تاقلاع ةسرامم وأ فتاهلا ربع ثدحتلا ،ماعطلا لوانتو ريضحت ،ةبكرملا .("ءاودلا لامعتسإب قلعتت ةصاخ تا Läs hela dokumentet
1 _ _ _ _ _AMBI-SPC-6.25MG-12.5MG-SPC-19.0 _ AMBIEN CR PRESCRIBING INFORMATION WARNING: COMPLEX SLEEP BEHAVIORS COMPLEX SLEEP BEHAVIORS INCLUDING SLEEP-WALKING, SLEEP-DRIVING, AND ENGAGING IN OTHER ACTIVITIES WHILE NOT FULLY AWAKE MAY OCCUR FOLLOWING USE OF AMBIEN CR. SOME OF THESE EVENTS MAY RESULT IN SERIOUS INJURIES, INCLUDING DEATH. DISCONTINUE AMBIEN CR IMMEDIATELY IF A PATIENT EXPERIENCES A COMPLEX SLEEP BEHAVIOR _[SEE CONTRAINDICATIONS (4) _ _AND WARNINGS AND PRECAUTIONS (8.1)]._ 1 NAME OF THE MEDICINAL PRODUCT AMBIEN CR 6.25 mg AMBIEN CR 12.5 mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each extended-release tablet of Ambien CR 6.25 mg contains zolpidem tartrate 6.25 mg Each extended-release tablet of Ambien CR 12.5 mg contains zolpidem tartrate 12.5 mg Excipients with known effect: Each Ambien CR 6.25 mg extended-release tablet contains 138.913 mg mg lactose monohydrate. Each Ambien CR 12.5 mg extended-release tablet contains 138.913 mg mg lactose monohydrate. For the full list of excipients, _see section 14_ . 3 PHARMACEUTICAL FORM Extended-release tablets. Ambien CR 6.25 mg extended-release tablets are: pink, round, bi-convex, engraved ZMR on one face. Ambien CR 12.5 mg extended-release tablets are: blue, round, bi-convex, engraved ZMR on one face 4 THERAPEUTIC INDICATIONS Ambien CR (zolpidem tartrate extended-release tablets) is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset). The clinical trials performed in support of efficacy were up to 3 weeks (using polysomnography measurement up to 2 weeks in both adult and elderly patients) and 24 weeks (using patient-reported assessment in adult patients only) in duration _ [see Clinical _ _Studies (17)]_ . 2 5 DOSAGE AND ADMINISTRATION 5.1 DOSAGE IN ADULTS Use the lowest effective dose for the patient. The recommended initial dose is 6.25 mg for women and either 6.25 or 12.5 mg for men, taken only once per night immediately before bedtime with at leas Läs hela dokumentet